Ldl receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Bieghs, Veerle ^a   Van Gorp, Patrick J ^a   Wouters, Kristiaan ^b   Hendrikx, Tim ^a   Gijbels, Marion J ^a   van Bilsen, Marc ^a   Bakker, Jaap ^a   Binder, Christoph J ^c   Lütjohann, Dieter ^d   Staels, Bart ^b   Hofker, Marten H ^e   Shiri Sverdlov, Ronit ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIV LILLE   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE MODEL; HYPERLIPIDEMIA; INFLAMMATION; KNOCKOUT MOUSE; LIVER FIBROSIS; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; ANIMAL; BLOOD; BONE MARROW CELL; C57BL MOUSE; CYTOLOGY; FATTY LIVER; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE TARGETING; GENETICS; HUMAN; IMMUNOLOGY; KUPFFER CELL; LIPID DIET; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; TIME;

ANIMALIA; MUS;

ANIMALS; APOLIPOPROTEIN E2; APOPTOSIS; BONE MARROW CELLS; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; GENE KNOCKOUT TECHNIQUES; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; KUPFFER CELLS; LIPOPROTEINS, LDL; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; TIME FACTORS;

EID: 84856297712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030668     Document Type: Article

References (42)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ, (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438.
2. Adams LA, Sanderson S, Lindor KD, Angulo P, (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42: 132-138.
3. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, et al. (2004) Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53: 750-755.
4. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873.
5. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, et al. (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58: 1538-1544.
6. Anstee QM, Goldin RD, (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16.
7. Larter CZ, Yeh MM, (2008) Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648.
8. Ludwig J, McGill DB, Lindor KD, (1997) Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 12: 398-403.
9. Choi SY, Fong LG, Kirven MJ, Cooper AD, (1991) Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest 88: 1173-1181.
10. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N, (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102: 130-135.
11. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48: 474-486.
12. Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH, (2005) Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med 43: 470-479.
13. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, et al. (2010) Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 138: 2477-2486, 2486 e2471-2473.
14. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114: 427-437.
15. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, et al. (1999) Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103: 117-128.
16. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, et al. (2003) Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 112: 1176-1185.
17. Ikejima K, Okumura K, Lang T, Honda H, Abe W, et al. (2005) The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 33: 151-154.
18. Schattenberg JM, Galle PR, (2010) Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28: 247-254.
19. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, et al. (2008) Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49: 1068-1076.
20. Wouters K, van Bilsen M, van Gorp PJ, Bieghs V, Lutjohann D, et al. (2010) Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 584: 1001-1005.
21. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
22. Kong B, Luyendyk JP, Tawfik O, Guo GL, (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328: 116-122.
23. Yoshimatsu M, Terasaki Y, Sakashita N, Kiyota E, Sato H, et al. (2004) Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic process. Int J Exp Pathol 85: 335-343.
24. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, et al. (2009) Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 104: e42-54.
25. Floreani A, (2007) Liver diseases in the elderly: an update. Dig Dis 25: 138-143.
26. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, et al. (2004) Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53: 1020-1023.
27. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL, (1981) Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci U S A 78: 7545-7549.
28. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM, (1985) Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 82: 203-207.
29. Lin CT, Xu YF, Wu JY, Chan L, (1986) Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J Clin Invest 78: 947-958.
30. Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D, (2001) Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol 12: 181-207.
31. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, et al. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353.
32. Zhang SH, Reddick RL, Burkey B, Maeda N, (1994) Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 94: 937-945.
33. Zhang SH, Reddick RL, Piedrahita JA, Maeda N, (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471.
34. Miyata M, Smith JD, (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14: 55-61.
35. Goldstein JL, Ho YK, Basu SK, Brown MS, (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 76: 333-337.
36. Henriksen T, Mahoney EM, Steinberg D, (1981) Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A 78: 6499-6503.
37. Mari M, Caballero F, Colell A, Morales A, Caballeria J, et al. (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4: 185-198.
38. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, et al. (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366-1374.
39. Koliwad SK, Streeper RS, Monetti M, Cornelissen I, Chan L, et al. (2010) DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J Clin Invest 120: 756-767.
40. Gabay C, (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8 (Suppl 2): S3.
41. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, et al. (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26: 39-45.
42. Han J, Hajjar DP, Febbraio M, Nicholson AC, (1997) Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 272: 21654-21659.